Early cancer detection startup Craif raises $22M

Cancer ranks as one of the best reasons for death in the world. National Cancer Institute In 2022 in 2022, in 2022, 20 million new cancers in 2022, 9.7 million cancers, 9.7 million cancers, rose to 29.9 million in 2040.

UnattractiveIn 2018, using the University of Nagoya, using the MicrogrA University, the AI ​​uses the EU-announced early cancer detection program and expand the US market and expand the US market and further expand the R & D.

Craif’s co-founder, co-founder and CEO Director-General TechCrunch said in an interview with a total of $ 100 million and the financial period of the C.

X & KSKAn investor, the first investment in the United States, the first investment in the Tauns Laboratories, DAIWA House industry and Aozora banking group, along with the first investment, leads to the latest financial financing.

When starting when the Craif started on his journey, it began how both grandparents and grandfather began with the diagnosis of the disease. These personal experiences inspired a strong commitment to resolve the issue of cancer. One and Takao Yasui, the associate professor of Nagoya University, a month after meeting, Craif Craif also wore. Yasui had created a new method for early cancer detection using urine biomarkers.

Early detection of a successful situation, such as blood tests can be difficult, such as traditional diagnostic methods can be invasive, cause some people to prevent regular examinations. In addition, limited access to medical institutions in certain areas is difficult to easily obtain the cancer test of individuals.

CRAIF allows you to detect early cancer, even as stage 1, solving these gaps, even as stage 1.

“The test can be carried out in the comfort of a patient’s home and is equipped with advanced micramnic analysis and makes early detection more accessible and effective.” “Our users are healthy healthy people who are concerned about cancer, but they find it difficult to commit conditional screens due to time, value and accessibility.”

Creates platforms for early cancer detection in several startup industry Put on, Freenome, Delifi Diagnostics and Clearnote Health.

CRAIF distinguishes itself using CFDNA (cellless DNA) as most competitors in Morcanda and uses urine.

“The mirna known after being a tuber 2024 Nobel PrizeIn the earliest stages, even in cancer biology are known in a deep participation, “he said.

Another unique side of his product is his urinary use. Urine, the urine, which provides many scientific and practical benefits, said it was easy and non-invasive. Biomarker has less impurities than other examples by making the signals more clearly. This helps to reduce any measurement errors as the hemolysis in the blood and save money in the tests.

Craif’s first product, manifi, incorrect, seven different cancers (pancreas, colectal, Colectal, Colectagus, lungs, stomach, and ova), income in Japan. According to CEO, clinics, pharmacies, pharmacies are distributed through direct consumer sales and corporate health programs, according to CEO, can be expanded.

“We serve about about 600 pharmacies in more than 1,000 medical institutions and about 600 pharmacies. Our team consists of 73 employees,” he said.

The income model offers both tests and subscription packages for regular testing with many users who prefer subscription plans. In 2024, he sent $ 5 million income and aims to earn $ 15 million by the end of this year.

Craig intends to expand the area to enter more than ten different types of cancers in the coming year. Moreover, it is preparing to use technology for early detection of cancerous diseases such as NevodeGenerative disorders such as Dementia.

Craifin Irvine has a R & D Laboratory in California and plans to open another office in San Diego to manage business operations.

The new financing will help the start to the US market together with the beginning of the United States, aiming to complete the tests in 2026 and get FDA approval in early 2027.

The United States has already begun to collect pancreatic cancer samples in cooperation with 30 medical institutions in the United States.